文献速递前列腺癌

前列腺癌主动监测转治疗时间相关因素的多机构队列研究

Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
PubMed 文献 · J Urol · 2021-09-10

多机构队列纳入6775例接受主动监测的前列腺癌患者,中位随访6.7年,33.4%转为治疗。较早转换与更高Gleason分级分组、PSA浓度、肿瘤分期、阳性穿刺针数及较年轻年龄相关;高体积GG1肿瘤的转换行为类似中高危患者。自报种族和遗传祖先与转换时间无显著关联。

要点

  • 高Gleason分级分组、高PSA、高临床分期、多阳性穿刺针数及较年轻年龄与较早转换相关。
  • 高体积GG1肿瘤的转换间隔短于低体积GG1,行为类似中高危患者。
  • 自报种族和遗传祖先与转换时间无显著关联。

核心结论

  • 主动监测转为治疗的时间较短与更高风险的临床病理肿瘤特征相关。
  • 高体积GG1肿瘤患者的转换行为类似中危和高危肿瘤患者。
  • 自报种族和遗传祖先与转换时间无显著关联。

研究设计与样本

  • 多机构队列研究,7279例接受主动监测的前列腺癌患者收集了数据和生物样本用于胚系遗传分析。
  • 最终分析纳入6775例男性,中位随访6.7年。

主要发现

  • 2260例(33.4%)在中位随访6.7年内转为治疗。
  • 较高Gleason分级分组与较早转换相关:GG2 vs GG1 aHR 1.57(95%CI 1.36-1.82);≥GG3 vs GG1 aHR 1.77(95%CI 1.29-2.43)。
  • 血清PSA每增加5 ng/ml的aHR为1.18(95%CI 1.11-1.25)。
  • 肿瘤分期与较早转换相关:cT2 vs cT1 aHR 1.58(95%CI 1.41-1.77);≥cT3 vs cT1 aHR 4.36(95%CI 3.19-5.96)。
  • 阳性穿刺针数与较早转换相关:3针 vs 1-2针 aHR 1.59(95%CI 1.37-1.84);≥4针 vs 1-2针 aHR 3.29(95%CI 2.94-3.69);年龄每增加5岁aHR 0.96(95%CI 0.93-0.99)。

关键数值与推荐

  • 较早转换相关因素包括较高Gleason分级分组、较高PSA浓度、较高肿瘤分期、较多阳性穿刺针数及较年轻年龄。
  • 高体积GG1肿瘤患者转换间隔短于低体积GG1肿瘤,行为类似更高风险患者。
  • 自报种族和遗传祖先与转换时间无显著关联。

临床怎么用

  • 对高Gleason分级分组、高PSA、高临床分期、多阳性穿刺针数及较年轻患者应预期更早转换并加强监测。
  • 高体积GG1肿瘤患者应视为转换风险较高人群,监测策略可参考中高危患者。
  • 自报种族和遗传祖先不作为转换时间的分层依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We examined the demographic and clinicopathological parameters associated with the time to convert from active surveillance to treatment among men with prostate cancer. MATERIALS AND METHODS: A multi-institutional cohort of 7,279 patients managed with active surveillance had data and biospecimens collected for germline genetic analyses. RESULTS: Of 6,775 men included in the analysis, 2,260 (33.4%) converted to treatment at a median followup of 6.7 years. Earlier conversion was associated with higher Gleason grade groups (GG2 vs GG1 adjusted hazard ratio [aHR] 1.57, 95% CI 1.36-1.82; ≥GG3 vs GG1 aHR 1.77, 95% CI 1.29-2.43), serum prostate specific antigen concentrations (aHR per 5 ng/ml increment 1.18, 95% CI 1.11-1.25), tumor stages (cT2 vs cT1 aHR 1.58, 95% CI 1.41-1.77; ≥cT3 vs cT1 aHR 4.36, 95% CI 3.19-5.96) and number of cancerous biopsy cores (3 vs 1-2 cores aHR 1.59, 95% CI 1.37-1.84; ≥4 vs 1-2 cores aHR 3.29, 95% CI 2.94-3.69), and younger age (age continuous per 5-year increase aHR 0.96, 95% CI 0.93-0.99). Patients with high-volume GG1 tumors had a shorter interval to conversion than those with low-volume GG1 tumors and behaved like the higher-risk patients. We found no significant association between the time to conversion and self-reported race or genetic ancestry. CONCLUSIONS: A shorter time to conversion from active surveillance to treatment was associated with higher-risk clinicopathological tumor features. Furthermore, patients with high-volume GG1 tumors behaved similarly to those with intermediate and high-risk tumors. An exploratory analysis of self-reported race and genetic ancestry revealed no association with the time to conversion.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Cooley LF, Emeka AA, Meyers TJ, et al. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol. 2021. PMID: 34503355. doi:10.1097/JU.0000000000001937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。